WAAW events: Global voices, FT’s antibiotic dashboard, JPIAMR calls, FAO Action Plan!

Dear All,

World Antimicrobial Awareness Week (WAAW) was such a mad scramble! So many events … just no way to attend everything.

Some of the highlights in and around WAAW (not everything was precisely within the WAAW dates, thank goodness!) for me were:

  • Andrew Jack and the team at FT (Financial Times) have released an antibiotic dashboard that tracks country- and company-level performance on AMR. Andrew and his colleagues are also responsible for an excellent 5-minute video explainer of the Netflix purchase model that the UK is piloting. It is very instructive to note that this financial newspaper has recognized the way that AMR can impact the business world!
  • FAO (the Food and Agriculture Organization of the UN) has released a 5-year Action Plan (2021-2025) for combating AMR in the food agriculture sector with objectives that include (1) Increasing stakeholder awareness and engagement, (2) Strengthening surveillance and research, (3) Enabling good practices, (4) Promoting responsible use of antimicrobials, and (5) Strengthening governance and allocating resources sustainably.
  • IDSA released v2.0 of its guidance for treating antimicrobial-resistant Gram-negative infections. As was discussed in this 9 Sep 2020 newsletter, this regularly updated guidance recognizes the need for summaries of what you’d learn if you had a day in library-land with an expert at your elbow. It’s a superb read!
  • FAO, OIE, and WHO (“the tripartite) released their Global Database for the Tripartite Antimicrobial Resistance (AMR)
    Country Self-assessment Survey (TrACSS)
    .
    Yes, that’s quite a mouthful … but very important! Of the 163 reporting countries to TrACSS this year, 140 countries reported having a national action plan endorsed, implementation and evaluation of those is less as you will see in the database. Progress!
  • Finally, JPIAMR has posted a heads-up on two calls that will be released early in 2022:

And if that wasn’t enough, then there were the webinars and video chats. I highlight below 4 that I especially enjoyed: Two substantive multi-speaker webinars and two fireside chats that I was able to host with colleagues around the world. I think that these global voices calling for action are very powerful … we are going to get there with the kind of Pull incentives needed to stabilize the antibiotic ecosystem. Enjoy!

The Global AMR Crisis; Does the scale of the action match the scale of the threat? Speakers include Hanan Balkhy (WHO), Ramanan Laxminaryan (CDDEP), Kevin Outterson (Boston University), David Paterson (U Queensland), Yasuhisa Shiozaki (AMR Global Leaders Group), and Lothar Weiler (Robert Koch Institute).

Ensuring Pull Incentives for Priority Antibiotics to Succeed. This superb (as usual) Duke-Margolis seminar includes speakers from Academia (Kevin Outterson, Boston University), national public health agencies (Christine Årdal from Public Health Norway; Nick Crabb from  the UK’s NICE, Lynn Filpi from US DHHS), CDC (Arjun Srinivasan), and more. More details (plus other materials from Duke-Margolis) can be found on the event website.

Fireside chat with Ghada Zoubiane, Head of Partnerships and Stakeholder Engagement at the International Centre for Antimicrobial Resistance Solutions (ICARS, based in Denmark) In this wide-ranging conversation, we cover everything from Ghada’s science journey to her views on how science can connect the world. Fun!

This fireside chat takes us to the Land Down Under to meet Trevor Lithgow, Director of the Centre to Impact AMR Strategy at Monash University, Victoria, Australia. Trevor’s journey began with studies of mitochondrial physiology and ultimately took him to working on phage as therapeutics! 

With gratitude for this amazing community, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All opinions are my own.


Current funding opportunities (most current list is here):

  • The AMR Action Fund is now open to proposals for funding of Phase 2 / Phase 3 antibacterial therapeutics. Per its charter, the fund prioritizes investment in treatments that address a pathogen prioritized by the WHO, the CDC and/or other public health entities that: (i) are novel (e.g., absence of known cross-resistance, novel targets, new chemical classes, or new mechanisms of action); and/or (ii) have significant differentiated clinical utility (e.g., differentiated innovation that provides clinical value versus standard of care to prescribers and patients, such as safety/tolerability, oral formulation, different spectrum of activity); and (iii) reduce patient mortality. It is also expected that such agents would have the potential to strongly address the likely requirements for delinked Pull incentives such as the UK (NHS England) subscription pilot and the PASTEUR Act in the US. Submit queries to contact@amractionfund.com.
  • INCATE (Incubator for Antibacterial Therapies in Europe) is a newly launched early-stage funding vehicle. Details are still coming into focus, but per comments on 25 Aug 2021 at the BIOCOM conference, their goal is to support ~4 companies per year with about $250k/company. Contact details are on their website (https://www.incate.net/).
  • CARB-X recently announced that their existing resources will be reserved to fund their existing portfolio (more than 80 total awards, and counting, as they include contracting from prior rounds). New rounds from CARB-X will occur only after new funding is obtained in 2021.
  • It’s not a funder, but AiCuris’ AiCubator offers incubator support to very early stage projects. Read more about it here.
  • The Global AMR R&D Hub’s dynamic dashboard (link) summarizes the global clinical development pipeline, incentives for AMR R&D, and investors/investments in AMR R&D.
  • In addition to the lists provided by the Global AMR R&D Hub, you might also be interested in my most current lists of R&D incentives (link) and priority pathogens (link).

Upcoming meetings of interest to the AMR community (most current list is here):

  • 8-9 Dec 2021 (virtual, 9a-noon East Coast US): ASM-ESCMID-sponsored joint conference on antimicrobial drug development. This is the 2021 online version of one of my favorite meetings and I strongly encourage attendance on both days to gain a perspective on how new reimbursement models are going to change the R&D landscape. Online agenda is here, registration link is pending so just mark your calendar for now.
    • 8 Dec: “The New Winds Pushing and Pulling Antibacterial Development.” DO NOT MISS THIS ONE! Featuring talks from the UK team behind the NHS “Netflix” pilot, Kevin Outterson’s recently released report documenting the need for global Pull incentives to have a value of $2.2 – 4.8b, and speakers covering PASTEUR and work in the EU on pull incentives, this promises to be a key update for the whole community.
    • 9 Dec: CARB-X – GARDP Boot Camp: What Makes a Good Project Succeed? Featuring speakers with many years of R&D experience, this session makes a good companion to the 8 Dec talk and will leave you well informed on best ways to guide your search for new antibiotics.
  • 14 Dec 2021 (virtual, 9a-1030a EST): CDC webinar entitled “Hooves, Paws, or Feet: A Multispecies Examination of Antimicrobial Use and Stewardship Practices”. This event is the third installment of the AMR Exchange webinar series. Click here for details.
  • 2-3 Feb 2022 (virtual): 10th Advances Against Aspergillosis and Mucormycocosis. Registration closes on 30 Jan 2022. Go here for details.
  • 2-3 Feb 2022 (virtual): Antimicrobial Chemotherapy Virtual Conference jointly organised by GARDP with the British Society for Antimicrobial Chemotherapy (BSAC), Center for Disease Dynamics, Economics & Policy (CDDEP) and the Indian Council of Medical Research (ICMR). Click here for details.
  • 3-6 Mar 2022 (Albuquerque, New Mexico): Biannual meeting of the MSGERC (Mycoses Study Group Education and Research Consortium). Details are here.
  • 6-11 Mar 2022 (Il Ciocco, Tuscany): Gordon Research Conference entitled “New Antibacterial Discovery and Development”. Go here for details, go here for the linked 5-6 Mar Gordon Research Seminar that precedes it.
  • 7-8 Apr 2022 (Basel and in person, we hope): The 6th edition of the annual AMR conference sponsored by the BEAM AllianceCARB-X, the Novo REPAIR Impact Fund, the IMI Accelerator, and the European Biotechnology Network. Go here for the hold-the-date page and a way to be kept informed about the meeting. 
  • 9-13 May 2022 (Athens and online): 40th Annual Meeting of the European Society for Paediatric Infectious Diseases, Go here for details.
  • 20-24 Sep 2022 (New Delhi): 21st Congress of the International Society for Human and Animal Mycology (ISHAM). Go here for details.
  • 25-28 Oct 2022 (Stellenbosch, South Africa): The University of Cape Town’s H3D Research Centre will celebrate its 10th anniversary with a symposium covering the Centre’s research on Malaria, TB, Neglected Tropical Diseases, and AMR. Go here to register.

https://www.youtube.com/watch?v=XZKuEWkJz7w

Fireside chat with Ghada Zoubiane, Head of Partnerships and Stakeholder Engagement at the International Centre for Antimicrobial Resistance Solutions (ICARS, based in Denmark) In this wide-ranging conversation, we cover everything from Ghada’s science journey to her views on how science can connect the world. Fun!

https://www.youtube.com/watch?v=clSFuAscPqQ
This fireside chat takes us to the Land Down Under to meet Trevor Lithgow, Director of the Centre to Impact AMR Strategy at Monash University, Victoria, Australia. Trevor’s journey began with studies of mitochondrial physiology and ultimately took him to working on phage as therapeutics! 

With gratitude for this amazing community, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All opinions are my own.


Current funding opportunities (most current list is here):

  • The AMR Action Fund is now open to proposals for funding of Phase 2 / Phase 3 antibacterial therapeutics. Per its charter, the fund prioritizes investment in treatments that address a pathogen prioritized by the WHO, the CDC and/or other public health entities that: (i) are novel (e.g., absence of known cross-resistance, novel targets, new chemical classes, or new mechanisms of action); and/or (ii) have significant differentiated clinical utility (e.g., differentiated innovation that provides clinical value versus standard of care to prescribers and patients, such as safety/tolerability, oral formulation, different spectrum of activity); and (iii) reduce patient mortality. It is also expected that such agents would have the potential to strongly address the likely requirements for delinked Pull incentives such as the UK (NHS England) subscription pilot and the PASTEUR Act in the US. Submit queries to contact@amractionfund.com.
  • INCATE (Incubator for Antibacterial Therapies in Europe) is a newly launched early-stage funding vehicle. Details are still coming into focus, but per comments on 25 Aug 2021 at the BIOCOM conference, their goal is to support ~4 companies per year with about $250k/company. Contact details are on their website (https://www.incate.net/).
  • CARB-X recently announced that their existing resources will be reserved to fund their existing portfolio (more than 80 total awards, and counting, as they include contracting from prior rounds). New rounds from CARB-X will occur only after new funding is obtained in 2021.
  • It’s not a funder, but AiCuris’ AiCubator offers incubator support to very early stage projects. Read more about it here.
  • The Global AMR R&D Hub’s dynamic dashboard (link) summarizes the global clinical development pipeline, incentives for AMR R&D, and investors/investments in AMR R&D.
  • In addition to the lists provided by the Global AMR R&D Hub, you might also be interested in my most current lists of R&D incentives (link) and priority pathogens (link).

Upcoming meetings of interest to the AMR community (most current list is here):

  • 8-9 Dec 2021 (virtual, 9a-noon East Coast US): ASM-ESCMID-sponsored joint conference on antimicrobial drug development. This is the 2021 online version of one of my favorite meetings and I strongly encourage attendance on both days to gain a perspective on how new reimbursement models are going to change the R&D landscape. Online agenda is here, registration link is pending so just mark your calendar for now.
    • 8 Dec: “The New Winds Pushing and Pulling Antibacterial Development.” DO NOT MISS THIS ONE! Featuring talks from the UK team behind the NHS “Netflix” pilot, Kevin Outterson’s recently released report documenting the need for global Pull incentives to have a value of $2.2 – 4.8b, and speakers covering PASTEUR and work in the EU on pull incentives, this promises to be a key update for the whole community.
    • 9 Dec: CARB-X – GARDP Boot Camp: What Makes a Good Project Succeed? Featuring speakers with many years of R&D experience, this session makes a good companion to the 8 Dec talk and will leave you well informed on best ways to guide your search for new antibiotics.
  • 14 Dec 2021 (virtual, 9a-1030a EST): CDC webinar entitled “Hooves, Paws, or Feet: A Multispecies Examination of Antimicrobial Use and Stewardship Practices”. This event is the third installment of the AMR Exchange webinar series. Click here for details.
  • 2-3 Feb 2022 (virtual): 10th Advances Against Aspergillosis and Mucormycocosis. Registration closes on 30 Jan 2022. Go here for details.
  • 2-3 Feb 2022 (virtual): Antimicrobial Chemotherapy Virtual Conference jointly organised by GARDP with the British Society for Antimicrobial Chemotherapy (BSAC), Center for Disease Dynamics, Economics & Policy (CDDEP) and the Indian Council of Medical Research (ICMR). Click here for details.
  • 3-6 Mar 2022 (Albuquerque, New Mexico): Biannual meeting of the MSGERC (Mycoses Study Group Education and Research Consortium). Details are here.
  • 6-11 Mar 2022 (Il Ciocco, Tuscany): Gordon Research Conference entitled “New Antibacterial Discovery and Development”. Go here for details, go here for the linked 5-6 Mar Gordon Research Seminar that precedes it.
  • 7-8 Apr 2022 (Basel and in person, we hope): The 6th edition of the annual AMR conference sponsored by the BEAM AllianceCARB-X, the Novo REPAIR Impact Fund, the IMI Accelerator, and the European Biotechnology Network. Go here for the hold-the-date page and a way to be kept informed about the meeting. 
  • 9-13 May 2022 (Athens and online): 40th Annual Meeting of the European Society for Paediatric Infectious Diseases, Go here for details.
  • 20-24 Sep 2022 (New Delhi): 21st Congress of the International Society for Human and Animal Mycology (ISHAM). Go here for details.
  • 25-28 Oct 2022 (Stellenbosch, South Africa): The University of Cape Town’s H3D Research Centre will celebrate its 10th anniversary with a symposium covering the Centre’s research on Malaria, TB, Neglected Tropical Diseases, and AMR. Go here to register.

Share

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
Share on reddit

PAR Foundation grants: Early career support, prevention of AMR in the elderly

Dear All, The Stockholm-based PAR Foundation (aka, the Foundation to Prevent Antibiotic Resistance) has announced two groups of grant opportunities. First, early career grants of up to ~€30k are available to support 1-year projects on prevention of antibiotic resistance. What: “The aim of this call is to improve the ability and interest of promising early-career individuals

BARDA and NIAID RFPs addressing bacterial, fungal, and viral threats

Dear All, When it rains, it pours … and sometimes in a good way! Today saw the release of requests for proposals by NIAID and BARDA for therapeutics (antibacterial, antifungal, antiviral), vaccines (again, all 3 areas), and diagnostics. It’s an impressive list of opportunities that covers both biothreat pathogens as well as NIAID’s list of

ARPEGE: New €17m French Consortium tackles economics, diagnostics, and therapeutics

Dear All, On 6 Jan 2022, we had the announcement of the creation of in France of the ARPEGE consortium (AppRoche théraPeutique Economique & diaGnostique de l’antibiorésistancE) or “Economic, diagnostic and therapeutic approach to antibiotic resistance.” Somebody definitely had fun with that acronym! Here’s what you need to know: The French government is providing €9m of

Scroll to Top